ID: ALA385925

Max Phase: Preclinical

Molecular Formula: C23H23F7N2O2

Molecular Weight: 492.44

Molecule Type: Small molecule

Representations

Canonical SMILES:  C[C@@H](O[C@H]1CC[C@@H](NCC(N)=O)[C@@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1

Standard InChI:  InChI=1S/C23H23F7N2O2/c1-12(14-8-15(22(25,26)27)10-16(9-14)23(28,29)30)34-19-7-6-18(32-11-20(31)33)21(19)13-2-4-17(24)5-3-13/h2-5,8-10,12,18-19,21,32H,6-7,11H2,1H3,(H2,31,33)/t12-,18-,19+,21+/m1/s1

Standard InChI Key:  BNZXSKJMIPTBKX-FRIZENJKSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 492.44

Molecular Weight (Monoisotopic): 492.1648

AlogP: 5.33

#Rotatable Bonds: 7

Polar Surface Area: 64.35

Molecular Species: BASE

HBA: 3

HBD: 2

#RO5 Violations: 1

HBA (Lipinski): 4

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 1

CX Acidic pKa:

CX Basic pKa: 8.68

CX LogP: 4.67

CX LogD: 3.37

Aromatic Rings: 2

Heavy Atoms: 34

QED Weighted: 0.51

Np Likeness Score: -0.40

References

1. Meurer LC, Finke PE, Owens KA, Tsou NN, Ball RG, Mills SG, Maccoss M, Sadowski S, Cascieri MA, Tsao KL, Chicchi GG, Egger LA, Luell S, Metzger JM, Macintyre DE, Rupniak NM, Williams AR, Hargreaves RJ..  (2006)  Cyclopentane-based human NK1 antagonists. Part 2: development of potent, orally active, water-soluble derivatives.,  16  (17): [PMID:16831551] [10.1016/j.bmcl.2006.06.044]

Source

Source(1):

• Scientific Literature